Anti-thrombotic therapy in infective endocarditis

Area of Science:

• Cardiology
• Infectious Diseases
• Hematology

Background:

• Infective endocarditis (IE) remains a serious condition with high morbidity and mortality.
• Systemic and central nervous system (CNS) embolization are major determinants of adverse outcomes in IE.
• IE vegetations involve complex interactions between pathogens, platelets, and the coagulation system.

Purpose of the Study:

• To review experimental and clinical data on anti-thrombotic treatment in infective endocarditis.
• To summarize current guidelines regarding anti-thrombotic therapy in IE.
• To assess the safety and efficacy of anti-thrombotic strategies in preventing embolic complications.

Main Methods:

• Review of experimental studies (in vitro and animal models) on anti-platelet and anti-coagulant effects in IE.
• Analysis of available clinical studies investigating anti-thrombotic treatments for IE.
• Summary of current international guidelines for IE management.

Main Results:

• Anti-platelet and anti-coagulant strategies impact IE vegetation formation and embolization in experimental models.
• Clinical study results on the efficacy of anti-thrombotic treatments in IE are conflicting.
• Continuation of existing anti-thrombotic treatment is considered safe in IE patients without hemorrhagic complications.

Conclusions:

• Early diagnosis, prompt antibiotic therapy, and judicious surgical intervention are crucial for preventing embolic complications in IE.
• While anti-thrombotic treatments show potential, their clinical application in IE requires further clarification due to conflicting data.
• Current guidelines suggest that continuing anti-thrombotic therapy is safe for IE patients with other indications, provided no bleeding occurs.